Carregant...
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficac...
Guardat en:
| Publicat a: | Biomol Ther (Seoul) |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
The Korean Society of Applied Pharmacology
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094065/ https://ncbi.nlm.nih.gov/pubmed/33731494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4062/biomolther.2021.032 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|